Trial’s controlled design was expected to quantify the original contribution of stem cells in the IMP. Credit: Petr Novák/Wikipedia.

Pharmaceutical firm ReGenTree has initiated a Phase III ARISE-3 clinical trial to evaluate drug candidate RGN-259 to treat patients with dry eye syndrome.

RGN-259 is a sterile, preservative-free eye drop formulation. It had been previously evaluated in the ARISE-1 and ARISE-2 trials, which were conducted on approximately 300 and 600 patients respectively.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ReGenTree was established in 2015 as a joint venture (JV) between RegeneRx Biopharmaceuticals and G-treeBNT to develop RGN-259 for dry eye syndrome and neurotrophic keratitis in the US.

ARISE-3 is a randomised double-masked, placebo-controlled trial based on ARISE-1 and ARISE-2 data.

ReGenTree has signed an agreement with clinical research services provider Ora to conduct the trial.

“We are pleased that ReGenTree has initiated ARISE-3 and look forward to moving RGN-259 through the FDA regulatory process.”

It will involve a total of 700 participants, with treatment estimated to be completed by the first half of next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

RegeneRx Biopharmaceuticals CEO JJ Finkelstein said: “We are pleased that ReGenTree has initiated ARISE-3 and look forward to moving RGN-259 through the FDA regulatory process, via ReGenTree or a partner, and into the market as soon as possible to treat this common disorder.”

The agreement will see G-treeBNT take responsibility for conducting and funding all clinical trials and product development through a new drug application (NDA) approval.

RegeneRx granted the JV an exclusive, royalty-bearing licence to market and sell RGN-259 in the US as part of the licencing agreement.

ReGenTree is also assessing RGN-259 in a 46-patient Phase III trial in neurotrophic keratopathy, where the product secured orphan drug designation from the US Food and Drug Administration (FDA).

RegeneRx has formed two alliances in Asia to develop the therapeutic for Asian patients with dry eye syndrome.